US Stock MarketDetailed Quotes
VTGN VistaGen Therapeutics
- 4.7400
- -0.0900-1.86%
Close May 1 16:00 ET
128.10MMarket Cap-1601P/E (TTM)
4.9300High4.7200Low132.04KVolume4.8500Open4.8300Pre Close635.87KTurnover0.87%Turnover RatioLossP/E (Static)27.03MShares24.710052wk High1.04P/B72.30MFloat Cap1.620052wk Low--Dividend TTM15.25MShs Float1889.9991Historical High--Div YieldTTM4.35%Amplitude1.6200Historical Low4.8150Avg Price1Lot Size
VistaGen Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | (FY)Mar 31, 2022 | (Q4)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 54.34%-4.54M | 62.12%-6.19M | 50.58%-7.89M | -9.85%-49.72M | 52.06%-7.47M | 17.54%-9.93M | -42.72%-16.34M | -158.68%-15.97M | -274.84%-45.26M | -195.13%-15.59M |
| Net income from continuing operations | 34.95%-6.35M | 62.32%-6.59M | 65.09%-6.9M | -24.05%-59.25M | 26.73%-12.23M | 7.35%-9.76M | -36.65%-17.48M | -155.36%-19.78M | -166.32%-47.76M | -168.70%-16.69M |
| Operating gains losses | ---- | ---- | ---- | --77.4K | --0 | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 8.32%143.2K | 5.81%140.3K | 6.73%138K | -25.30%531.2K | 2.77%137.1K | -58.16%132.2K | -0.23%132.6K | 0.39%129.3K | 48.89%711.1K | 0.45%133.4K |
| Other non cash items | ---- | ---- | ---- | --3.56M | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | 203.24%1.16M | -1,388.13%-325.9K | -162.27%-1.69M | 205.75%2.03M | 204.78%456.3K | 55.77%-1.13M | -104.89%-21.9K | 338.79%2.72M | -162.33%-1.92M | -242.32%-435.5K |
| -Change in prepaid assets | -114.34%-87K | -62.72%496.1K | -118.82%-207.2K | 265.79%3.19M | -21.12%150.5K | 293.83%606.5K | 274.76%1.33M | 205.88%1.1M | -485.63%-1.92M | 158.14%190.8K |
| -Change in payables and accrued expense | 118.38%268.7K | 78.08%-450.3K | -160.42%-1.21M | -155.30%-932.8K | 218.08%576.7K | 3.38%-1.46M | -226.52%-2.05M | -2.83%2.01M | 3,207.65%1.69M | -143.71%-488.4K |
| -Change in other current liabilities | -13.88%-124.7K | -12.14%-120.1K | -8.87%-114.2K | 36.00%-433.3K | -8.86%-111.8K | 72.60%-109.5K | -18.74%-107.1K | -24.14%-104.9K | -115.95%-677K | -24.03%-102.7K |
| -Change in other working capital | 780.70%1.11M | -131.11%-251.6K | 42.74%-160.9K | 120.50%205.9K | -351.99%-159.1K | 49.81%-162.7K | 349.29%808.7K | 12.41%-281K | -127.39%-1M | 91.21%-35.2K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 54.34%-4.54M | 62.12%-6.19M | 50.58%-7.89M | -9.85%-49.72M | 52.06%-7.47M | 17.54%-9.93M | -42.72%-16.34M | -158.68%-15.97M | -274.84%-45.26M | -195.13%-15.59M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -158.40%-32.3K | 0 | 0 | -269.41%-740.3K | -528,200.00%-528.3K | -12,600.00%-12.5K | 51.68%-24.4K | -16.81%-175.1K | 27.23%-200.4K | 99.61%-100 |
| Net PPE purchase and sale | -158.40%-32.3K | --0 | --0 | -5.79%-212K | --0 | -12,600.00%-12.5K | 51.68%-24.4K | -16.81%-175.1K | 27.23%-200.4K | 99.61%-100 |
| Net business purchase and sale | ---- | ---- | ---- | ---528.3K | ---- | ---- | ---- | ---- | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -158.40%-32.3K | --0 | --0 | -269.41%-740.3K | -528,200.00%-528.3K | -12,600.00%-12.5K | 51.68%-24.4K | -16.81%-175.1K | 27.23%-200.4K | 99.61%-100 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 30,852.55%93.52M | 10,332.25%34.18M | 16,020.00%875.6K | -109.94%-1.04M | -1,782.28%-398.7K | -114.35%-304.1K | -104.54%-334K | -100.55%-5.5K | -90.81%10.48M | -99.42%23.7K |
| Net issuance payments of debt | 99.84%-500 | -154.57%-784.6K | -96.58%-200.9K | -34,430.00%-1.04M | -157,100.00%-314.4K | -31,010.00%-311.1K | -34,144.44%-308.2K | -11,255.56%-102.2K | 99.21%-3K | 99.80%-200 |
| Net common stock issuance | --93.52M | 115,480.53%34.96M | 2,277.61%1.07M | -101.57%-69.5K | -129.81%-84.3K | --0 | -100.76%-30.3K | 1.35%45.1K | -95.95%4.44M | 1,763.53%282.8K |
| Proceeds from stock option exercised by employees | -47.14%3.7K | --0 | -91.86%4.2K | -98.96%63.1K | --0 | -99.65%7K | -99.86%4.5K | -95.35%51.6K | 20.73%6.05M | -106.16%-258.9K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 30,852.55%93.52M | 10,332.25%34.18M | 16,020.00%875.6K | -109.94%-1.04M | -1,782.28%-398.7K | -114.35%-304.1K | -104.54%-334K | -100.55%-5.5K | -90.81%10.48M | -99.42%23.7K |
| Net cash flow | ||||||||||
| Beginning cash position | 6.58%37.61M | -81.49%9.62M | -75.58%16.64M | -33.92%68.14M | -70.09%25.04M | -62.31%35.29M | -46.83%51.99M | -33.92%68.14M | 7,508.91%103.11M | -19.77%83.7M |
| Current changes in cash | 967.82%88.95M | 267.59%27.99M | 56.56%-7.02M | -47.25%-51.5M | 46.03%-8.4M | -3.25%-10.25M | -302.41%-16.7M | -202.90%-16.15M | -134.37%-34.97M | -1,172.89%-15.56M |
| End cash Position | 405.48%126.56M | 6.58%37.61M | -81.49%9.62M | -75.58%16.64M | -75.58%16.64M | -70.09%25.04M | -62.31%35.29M | -46.83%51.99M | -33.92%68.14M | -33.92%68.14M |
| Free cash flow | 54.07%-4.57M | 62.18%-6.19M | 51.12%-7.89M | -9.83%-49.93M | 52.06%-7.47M | 17.43%-9.95M | -42.30%-16.37M | -155.32%-16.14M | -268.10%-45.46M | -193.71%-15.59M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg